



Interim Report Q4 and Full Year 2025

Announcement no.5/2026

Sveinn Sölvason, President and CEO, comments:

"We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025.

Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish to the year, meanwhile sales in Bracing & Supports ended flat.

The EBITDA margin came in at 19% compared to 21% in Q4 2024. The margin was positively impacted by strong sales growth and manufacturing efficiency but negatively impacted by FX, tariffs, and initiatives to enhance long-term growth and profitability in our Patient Care segment.

Across markets, geographies, and patient care settings, 2025 was a year of meaningful progress for Embla Medical. The fundamental need for our solutions remains as strong as ever despite an increasingly uncertain geopolitical environment. For 2026 we are issuing new guidance of 5-8% organic sales growth and an EBITDA margin of 20-22%"

Highlights Q4 2025

- Sales amounted to USD 257 million and organic growth was 7%, compared to 5% in Q4 2024. Local currency sales growth was 10% including acquisitions and 14% reported growth in USD. For FY 2025 organic sales growth was 6%.
- Prosthetics & Neuro Orthotics (P&NO) sales grew by 9% organic, Bracing & Supports (B&S) sales ended flat, while Patient Care delivered 5% organic sales growth in Q4 2025. For FY 2025, Prosthetics & Neuro Orthotics sales grew 10% organic, Bracing & Supports sales declined by 1% while Patient Care sales grew by 1% organic. Growth in 2025 was driven by Prosthetics & Neuro Orthotics, mainly with a strong performance in EMEA and supported by recently launched innovation.
- Gross Profit was USD 158 million and gross profit margin was 62% for both Q4 2025 and FY 2025, compared to 63% in Q4 2024 and FY 2024. The gross profit margin was positively impacted by strong sales in P&NO and efficiency gains in manufacturing but was offset by negative impact from FX, tariffs, and initiatives in Patient Care.
- EBITDA amounted to USD 48 million and EBITDA margin was 19% of sales. In FY 2025, EBITDA margin was 20% on par with FY 2024. The EBITDA margin was negatively impacted by a lower gross profit margin, FX, and initiatives in Patient Care to strengthen growth and profitability.
- Net profit grew by 33% and was USD 25 million and net profit margin was 10% of sales in Q4, compared to 8% of sales in Q4 2024. The FY 2025 net profit growth was 21%.
- Free cash flow (FCF) amounted to USD 42 million, or 16% of sales compared to 15% of sales in Q4 2024. In FY 2025, FCF amounted to USD 100 million or 11% of sales compared to 9% of sales in FY 2024, benefiting from strong operating results and lower CAPEX.
- NIBD/EBITDA before special items was 2.4x at the end of Q4 2025 on par with Q4 2024 and within the target ratio of 2-3x EBITDA.

Other highlights

- Embla Medical earned a place among the world's top 500 companies, pairing strong growth with environmental responsibility. This was the 2nd consecutive year Embla Medical was highlighted as one of the World's Best Companies in Sustainable Growth.
- In November 2025 announced the opening of its new prosthetic clinic in Kyiv alongside a landmark partnership with the Government of Iceland to launch the "Iceland Supports Mobility in Ukraine" initiative, a three-year program designed to deliver high-quality prosthetic care and rehabilitation to up to 1,000 Ukrainian amputees.

2026 Outlook

- Organic sales growth guidance of 5-8%, driven by strong volume growth in the core business with moderate price increases.
- EBITDA margin guidance of 20-22%, driven by scale and efficiency coupled with continued focus on cost control in SG&A.

	2025	2024	Q4 2025	Q4 2024	2026 Guidance
Sales growth, organic	6%	6%	7%	5%	5-8%
EBITDA margin, before special items	20%	20%	19%	21%	20-22%*

*Potential impact from US trade tariffs continues to be an uncertain element to quantify given the frequent changes in the global tariff environment. Consequently, we deem it too speculative to quantify and guide an exact impact from potential tariffs on Embla Medical's financial results, but some absorption of tariffs is assumed in the guidance.

USD millions	Q4 2025	Q4 2024	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Income Statement							
Net sales	257	225	929	855	786	719	719
Gross profit	158	142	579	535	486	440	455
Operating expenses (excl. other income / exp.)	126	110	454	422	398	373	360
EBITDA	48	47	186	169	139	114	149
EBITDA before special items	48	47	186	173	139	128	149
EBIT	32	32	125	113	89	65	97
Net profit	25	19	84	69	59	43	66
Sales Growth							
Sales growth USD	% 14	7	9	9	9	0	14
Growth breakdown:							
Organic growth	% 7	5	6	6	9	4	10
Currency effect	% 5	(1)	2	0	(1)	(7)	3
Acquired business	% 3	3	1	3	1	3	1
Balance Sheet							
Total assets	1,730	1,539	1,730	1,539	1,386	1,325	1,247
Equity	896	781	896	781	705	636	627
Net interest-bearing debt (NIBD)	439	414	439	414	395	404	363
Cash Flow							
Cash generated by operations	63	54	178	160	126	92	128
Free cash flow	42	34	100	77	52	35	74
Key Ratios							
Gross profit margin	% 62	63	62	63	62	61	63
EBIT margin	% 13	14	13	13	11	9	14
EBITDA margin	% 19	21	20	20	18	16	21
EBITDA margin before special items	% 19	21	20	20	18	18	21
Equity ratio	% 52	51	52	51	51	48	50
Net debt to EBITDA before special items*	2.4	2.4	2.4	2.4	2.8	3.2	2.4
Effective tax rate	% 19	25	23	24	23	23	24
Return on equity*	% 10	9	10	9	9	7	11
CAPEX / Net sales	% 3.1	3.6	3.4	4.6	5.4	3.6	3.7
Market							
Market value of equity	2,202	2,125	2,202	2,125	1,713	2,035	2,724
Number of shares in millions	430	428	430	428	421	423	423
Basic EPS in US cents	5.8	4.4	19.6	16.2	14.0	10.3	15.6
Diluted EPS in US cents	5.8	4.4	19.6	16.2	14.0	10.3	15.5

Management's report

Financial performance

Sales

Sales increased by 7% organic in Q4 2025

Positive FX impact of USD 11 million in Q4 2025

Sales in FY 2025 amounted to USD 929 million, compared to USD 855 million in 2024, corresponding to 6% organic growth, a 7% increase including acquisitions (local currency growth) and 9% reported growth (USD growth). Sales in Q4 2025 amounted to USD 257 million, compared to USD 225 million in Q4 2024, corresponding to 7% organic growth, a 10% increase including acquisitions (local currency growth) and a 14% reported growth (USD growth).

Impact on sales from acquisitions amounted to USD 10 million in Q4 2025 corresponding to about a 3%-point positive effect on the reported growth rate. Currency impact on reported sales was positive by 5%-point or USD 11 million in Q4 2025, mainly due to a stronger EUR against the USD.

Sales by geographical segment (USD million)	Q4 2025	Organic growth	Δ Acq. / div.	Δ Curr. effect	USD growth	FY 2025	Organic growth	Δ Acq. / div.	Δ Curr. effect	USD growth
EMEA	131	12%	7%	11%	30%	457	8%	2%	5%	16%
Americas	107	0%	0%	0%	1%	399	2%	0%	0%	1%
APAC	19	9%	0%	(1%)	8%	73	11%	0%	(2%)	8%
Total	257	7%	3%	5%	14%	929	6%	1%	2%	9%

Sales by business segment (USD million)	Q4 2025	Organic growth	Δ Acq. / div.	Δ Curr. effect	USD growth	FY 2025	Organic growth	Δ Acq. / div.	Δ Curr. effect	USD growth
Prosthetics & Neuro Orthotics	141	9%	6%	4%	19%	513	10%	2%	2%	14%
Bracing & Supports	37	0%	0%	3%	2%	148	(1%)	0%	1%	0%
Internal product sales	(10)	(4%)	0%	0%	(3%)	(39)	0%	0%	2%	1%
External sales	168	7%	5%	4%	16%	623	8%	2%	2%	11%
Patient Care	89	5%	0%	6%	11%	306	1%	0%	3%	4%
Total	257	7%	3%	5%	14%	929	6%	1%	2%	9%

Growth in Q4 2025 was driven by strong volume growth and positive product mix in P&NO in addition to solid recovery in Patient Care. Both EMEA and APAC regions delivered strong growth in the quarter.

Strong EMEA growth in Prosthetics & Neuro Orthotics

Sales growth in the EMEA region was strong in the fourth quarter with 12% organic growth. The strong growth momentum in P&NO continued across most European markets driven by solid uptake of recently launched solutions including Navii (bionic knee) and Pro-Flex Terra (mechanical feet solution). In addition, the newly acquired Streifeneder ortho.production contributed with strong organic growth in Q4. Sales in B&S remained soft in the region, while sales in Patient Care picked up strongly across most European markets.

Sales in Americas ended flat in Q4 mainly due to tough comparisons with Q4 2024 in both P&NO and Patient Care. Sales growth in P&NO was moderate, supported by good growth in Bionics. Sales in B&S remained flat in Americas while sales in Patient Care ended down in Q4 in line with expectations due to a very strong comparison in Q4 2024. Despite a decline in sales in Patient Care in Americas we see encouraging signs of recovery with most regions delivering decent growth despite a strong comparable quarter.

In APAC organic sales growth was 9% in Q4 2025. Growth was supported by a strong performance in our Patient Care segment following a solid finish to the year. Sales performance in P&NO was moderate in the fourth quarter supported by strong growth in Australia, which was partly offset by softer performance in Asia. Sales in B&S were soft in Q4 despite solid growth in Australia and New Zealand.

In Neuro Orthotics (Fior & Gentz) the business is tracking in line with expectations following the expansion into multiple new international markets in the last 12-18 months. Sales in the fourth quarter was solid driven by continued growth momentum in our existing German business and supported by good uptake in new markets such as Australia and France. Americas is slowly ramping up following a new reimbursement code secured in the US last summer for our first bionic knee joint “NEURO HiTRONIC MPKAFO”, which is the smallest and lightest microhydraulic knee joint on the market today.

Sales in Bracing & Supports were soft in Q4 and FY with some regional variances. Sales continue to be impacted by shifting market dynamics and price sensitivity causing partial loss of business, in addition to increasing competitive pressure. Growth is expected in 2026 with focused initiatives and new product launches.

As communicated in the third quarter of 2025, our Patient Care business has over the last few quarters experienced lower than expected growth, mainly in EMEA and Americas regions. The performance can partly be ascribed to softness and timing in patient volumes but also internal change initiatives including the ForMotion rebranding, system integrations, and other change management initiatives temporarily impacting the business. Several initiatives have been implemented in Patient Care during the second half of the year with focus on performance management to strengthen growth and profitability. Costs related to these initiatives were incurred during the quarter and the year and are further described below. It is management’s ambition to get the Patient Care business back on track and deliver in line with the structural growth in the O&P industry.

Gross profit margin of 62% in Q4 2025	<p>Operations</p> <p>Gross profit in 2025 amounted to USD 579 million or 62% of sales, compared to USD 535 million or 63% of sales in 2024. Gross profit in Q4 2025 amounted to USD 158 million or 62% of sales, compared to USD 142 million or 63% of sales in Q4 2024. The gross profit margin was positively impacted by strong sales in P&NO and efficiency gains in manufacturing but offset by FX, tariffs, and initiatives in Patient Care.</p>
OPEX ratio of 49% in Q4 2025	<p>Operating expenses (OPEX)</p> <p>Operating expenses, excluding other income, amounted to USD 454 million or 49% of sales in FY 2025, compared to USD 422 million or 49% of sales in FY 2024. Operating expenses, excluding other income, amounted to USD 126 million or 49% of sales in Q4 2025, compared to USD 110 million or 49% of sales in Q4 2024.</p> <p>OPEX grew organically 7% in the fourth quarter but excluding the initiatives in Patient Care, OPEX grew organic below sales growth in line with continued focus on cost control in SG&A.</p>
EBITDA margin of 19% in Q4 2025	<p>EBITDA</p> <p>In FY 2025 EBITDA amounted to USD 186 million or 20% of sales, compared to EBITDA before special items of USD 173 million or 20% of sales in FY 2024 (USD 169 million reported or 20% of sales in FY 2024). In Q4 2025, EBITDA amounted to USD 48 million or 19% of sales, compared to EBITDA of USD 47 million or 21% of sales in Q4 2024.</p> <p>The negative effects on EBITDA margin from changes in currencies amounted to roughly 90 basis points in Q4 and 30 basis points in 2025 when compared to same periods in 2024.</p> <p>EBITDA margin decreased in the quarter compared to Q4 2024 due to FX, tariffs, and initiatives in Patient Care totaling approx. USD 2 million in Q4 and approx. USD 6 million FY 2025. These include restructuring costs in the form of severance, ForMotion rebranding, and system implementations impacting both COGS and OPEX. Total negative impact on EBITDA margin from the Patient Care initiatives and other items mentioned combined amounted to ~3%-points in Q4 and ~1.5%-points in FY 2025.</p>
Effective tax rate of 19% in Q4 2025	<p>Financial items, income tax and net profit</p> <p>Net financial expenses in 2025 amounted to USD 24 million, compared to USD 26 million in FY 2024. Net financial expenses in Q4 2025 amounted to USD 3 million, compared to USD 8 million in Q4 2024. The decrease in financial expenses in Q4 2025 compared to Q4 2024 is mainly related to lower financial expenses following a period with lower interest rates and positive impact from net exchange rate differences.</p> <p>Income tax amounted to USD 24 million in 2025, corresponding to a 23% effective tax rate, compared to USD 22 million in 2024, corresponding to a 24% effective tax rate. Income tax in Q4 amounted to USD 6 million, corresponding to a 19% effective tax rate, compared to USD 6 million in Q4 2024, corresponding to a 25% effective tax rate. The effective tax rate was lower in Q4 due to processing of certain tax credits. The tax rate for the full year is in line with guidance.</p>
Net profit margin of 10% in Q4 2025	<p>Net profit increased by 21% in 2025 and amounted to USD 84 million or 9% of sales, compared to USD 69 million or 8% of sales in 2024. Net profit grew 33% and amounted to USD 25 million or 10% of sales in Q4 2025, compared to USD 19 million or 8% of sales in Q4 2024.</p> <p>Diluted earnings per share in 2025 amounted to 19.6 US cents, compared to 16.2 in 2024. Diluted earnings per share in Q4 2025 amounted to 5.8 US cents, compared to 4.4 in Q4 2024.</p>

Cash flow

Cash generated by operations

Cash generation of USD 63 million in Q4 2025

Cash generated by operations amounted to USD 178 million or 19% of sales in 2025, compared to USD 160 million or 19% of sales in 2024. Cash generated by operations amounted to USD 63 million or 25% of sales in Q4 2025, compared to USD 54 million or 24% of sales in Q4 2024.

Cash generation was strong in FY 2025, mainly due to increased sales and strong operating results.

Capital expenditures

CAPEX was 3% of sales in Q4 2025

Capital expenditures in 2025 amounted to USD 32 million or 3% of sales, compared to USD 39 million or 5% of sales in 2024. Capital expenditures in Q4 2025 amounted to USD 8 million or 3% of sales, compared to USD 8 million or 4% of sales in Q4 2024.

CAPEX in 2025 returned to a normalized level around 3% following closure of facility expansion programs carried out in 2024 to support future growth.

Free cash flow

Free cash flow was 16% of sales in Q4 2025

Free cash flow in 2025 amounted to USD 100 million or 11% of sales, compared to USD 77 million or 9% of sales in 2024. Free cash flow in Q4 2025 amounted to USD 42 million or 16% of sales, compared to USD 34 million or 15% of sales in Q4 2024.

Solid free cash flow in the quarter was driven by good operating results, positive contribution from net working capital and normalized levels of CAPEX.

Bank balances and cash equivalents

Cash and undrawn facilities amounted to USD 217 million

Bank balances and cash equivalents amounted to USD 103 million at the end of Q4 2025 and USD 114 million of existing facilities were undrawn. Bank balances and cash equivalents in addition to undrawn credit facilities at the end of Q4 2025, therefore, amounted to USD 217 million.

Capital structure

Net-interest bearing debt

NIBD/EBITDA before special items at 2.4x

Net interest-bearing debt, including lease liabilities, amounted to USD 439 million at quarter-end Q4 2025 compared to USD 414 million at quarter-end Q4 2024. Net interest-bearing debt to EBITDA before special items corresponded to 2.4x at quarter-end Q4 2025, within the target range of 2.0-3.0x.

Share buybacks and treasury shares

Share buybacks of USD 2.7 million in Q4 2025

The purpose of the program is to reduce the Company's share capital and adjust the capital structure with a desired capital level of 2.0-3.0x net interest-bearing debt to EBITDA before special items, by distributing capital to shareholders in line with the Company's Capital Structure and Capital Allocation Policy.

During Q4 2025, Embla Medical bought back 538,017 shares at a market value of USD 2.7 million. At the end of Q4 2025, treasury shares totaled 2,673,596.

Financial guidance

Guidance	Guidance FY 2026	Actual FY 2025
Sales growth, organic	5-8%	6%
EBITDA margin before special items	20-22%	20%
For modelling purposes		
CAPEX as % of sales	3-4%	3%
Effective tax rate	23-24%	23%

For 2026 organic sales growth is expected to be in the range of 5-8%. We anticipate continued strong momentum in our Prosthetics & Neuro Orthotics business across regions supported by solid contributions from our fast-growing bionic portfolio and recently launched innovations in addition to upcoming launches in 2026. Some positive impact from the US Medicare Coverage Expansion is also expected to contribute to sales supported by our existing portfolio of microprocessor knee (MPK) solutions, which in the future will be complemented by a dedicated K2 MPK solution to better serve the least mobile users in the low active K2 patient population.

In Neuro Orthotics we expect to see the increasing effects from the ongoing roll out of our Neuro Orthotics offerings (Fior & Gentz) into new markets leveraging our global commercial infrastructure and ForMotion footprint within O&P Clinics. Albeit growing from a low base we expect to see solid growth in the EMEA region with some contributions expected in Americas in the course of 2026 as we prepare ramp-up for a broader launch of our first bionic knee joint “NEURO HiTRONIC MPKAFO”, which received a reimbursement code last summer in the important US market.

In Patient Care, we expect growth to gradually improve during 2026 with the aim of eventually returning to consistent sales performance in line with market. Growth in 2026 is expected to be driven by volume growth, increased efficiency supported by effects from the initiatives implemented across our Patient Care business in the second half of 2025. Focus will be on strengthening growth and profitability and benefiting from the structural growth in the O&P industry our product business has observed in recent periods.

Lastly, Bracing & Supports is expected to grow approximately in line with market growth. We assume solid growth in selected key regions supported by expected launches of new product categories but also with continued competitive pressure in selected markets.

EBITDA margin is expected in the range of 20-22% for 2026 compared to 20% in 2025. The EBITDA margin is expected to be positively impacted by solid sales performance, a favorable product mix from increased sales of our high-end solutions, continued efficiency gains in manufacturing, increasing profitability in Patient Care, and cost control in SG&A.

At current foreign exchange rates, keeping all other factors constant, the EBITDA margin is expected to be negatively impacted by about 30 basis points in 2026 when compared to 2025.

Foreign exchange

Sales are particularly exposed to fluctuations in the EUR/USD exchange rate. Additionally, the ISK has a relatively high impact on operating results as part of manufacturing, R&D and some corporate functions are based in Iceland, while sales in ISK are minimal. A breakdown of sales and costs by main currencies can be found in note 4 of the accompanying Condensed Consolidated Financial Statements.

All else being equal, a +/- 5% movement in EUR/USD is estimated to have an annual impact on EBITDA in the range of +/- USD 3.5-4.5 million when unhedged. The same movement in ISK/USD is estimated to have an annual impact on EBITDA in the range of +/- USD 4.0-5.0 million when unhedged. Embla Medical utilizes forward contracts to hedge approximately 50% of the estimated net currency exposure to ISK.

Currency overview USD	EUR	ISK
Average exchange rate FY 2025	1.130	0.0078
Opening rate February 2 2026	1.185	0.0081
Estimated average exchange rate for FY 2026*	1.185	0.0081
Change in estimated exchange rate FY 2026 compared to last year's average	5%	4%

*Estimated average exchange rate is calculated as exchange rate (open) on Feb 2, 2026, for the remainder of the year

Other highlights

Embla Medical Expands Support for Ukrainian Amputees with New Kyiv Clinic and Iceland Partnership

In November 2025 announced the opening of its new prosthetic clinic in Kyiv alongside a landmark partnership with the Government of Iceland to launch the "Iceland Supports Mobility in Ukraine" initiative, a three-year program designed to deliver high-quality prosthetic care and rehabilitation to up to 1,000 Ukrainian amputees.

One of the world's best companies in sustainable growth 2026

For the 2nd consecutive year, Embla Medical has earned a place among the world's top 500 companies, pairing strong growth with environmental responsibility. We ranked #63 overall and sixth within the Engineering, Manufacturing & Medical Technology sector, with an outstanding score of 88.88 / 100. The ranking, developed by TIME and Statista, recognizes companies that demonstrate transparent environmental reporting and evaluates performance across three key areas: revenue growth, financial stability, and environmental impact.

Section 232 investigations on MedTech equipment

On 26 September 2025, the US Department of Commerce published a notice for a public consultation on a possible Section 232 Investigation concerning robotics/industrial machinery as well as personal protective equipment (PPE), medical consumables and medical equipment including devices such as hearing aids, prosthetics, orthopedic appliances, ventilators and respirators etc. The objective is to determine the effects on the US national security of imports of these goods. We are currently assessing the scope and potential implications of the Section 232 investigation and the potential trade restrictions that might result from this. As several factors remain uncertain at this stage, we deem it to be too premature to discuss potential impact until more clarity has been revealed.

ForMotion: Completion of rebranding expected in Q1 2026

In Q4 2025 several patient care facilities in the United States and Australia were rebranded to ForMotion. The global rebranding roll-out is expected to be completed in Q1 2026.

Product launches during the last 12 months

Launch quarter	Segment	Product name	Product description
Q4 2025	Prosthetics Bionic knee	Power Knee™ Update (Össur)	Power Knee™ controls have been updated to deliver functional improvements that enhance mobility and adoption of powered solutions. Synchronous Control™ provides natural, powered motion that adapts seamlessly to each step at any walking speed. Sit-to-stand assistance can now be smoothly ramped and tailored to user preference, while improved stair and stumble-recovery functions deliver more natural transitions and support when it is needed most.
Q3/Q4 2025	Prosthetics Ankle	Pro-Flex® LP Junior (Össur)	Designed for active young users, the Pro-Flex® LP Junior delivers exceptional ankle range and power, enhanced durability and waterproof performance. , and a smooth, natural gait using proven three-blade technology and a split-toe design. Built with the proven Pro-Flex three-blade technology and split toe design, it promotes a smooth, natural gait combined with comfort and control every day.
Q2/Q3 2025	Prosthetics Bionic foot	Odyssey® iQ (College Park)	The new Odyssey® iQ microprocessor foot is hydraulically dampened, lightweight, and low-profile. With an IP67 rating, long-lasting battery, and fast responses, it accommodates a wide range of users and activities.
Q2 2025	Prosthetics Socket	AeroFit® by (Össur)	AeroFit® is a breathable prosthetic interface system combining a vented socket with a 3D-printed silicone liner to significantly reduce humidity inside the prosthesis. Excess moisture is a common cause of discomfort and skin issues for lower-limb.
Q1 2025 (Limited launch Q2 2024)	Prosthetics Bionic knee	Icon® (College Park)	Icon® features responsive sensors, streamlined setup, and the intuitive Stride Studio app. Icon® is the versatile solution for low to high activity users.
Q1 2025 (Limited launch Q2 2024)	Prosthetics Bionic knee	Navii® (Össur)	Navii® is a fully waterproof bionic knee featuring a powerful actuator provided to support consistency for stair and ramp descent. Navii® possesses a variable-position mechanical lock that can securely lock at three different angles and stay locked for standing during longer periods of time.

Conference call and financial calendar

Conference call details

Embla Medical will host a conference call on February 3, 2026, at **9:00 CET / 7:00 GMT / 3:00 ET**.

To actively participate in the telephone conference, please use the dial-in details provided below:

DK: +45 78 76 84 90

UK: +44 20 3769 6819

US: +1 646 787 0157

Participant access code: 274982

The webcast will be available through following link: [Embla Medical Q4/FY 2025 webcast](#)

Financial calendar and events 2026

February 3, 2026	Q4 Report 2025 & 2025 Annual Report
February 3, 2026	Q4/FY 2025 HCA Capital virtual presentation and Q&A
February 3, 2026	Q4/FY 2025 Investor Road Show, Copenhagen (Nordea)
February 4, 2026	Q4/FY 2025 Investor Road Show, Stockholm (Nordea)
February 4, 2026	Q4/FY 2025 Investor Road Show, Paris (ABG)
February 5, 2026	Q4/FY 2025 Investor Road Show, London (Berenberg)
February 5, 2026	Q4/FY 2025 Investor Road Show, Zürich (Berenberg)
February 6, 2026	Q4/FY 2025 Investor Road Show, Reykjavik (Embla HQ)
February 9, 2026	Virtual Investor Group Call with Embla Medical CEO (Jefferies)
February 10, 2026	Aktiespararna Company Event, Falkenberg Sweden
March 10, 2026	2026 Annual General Meeting
March 11, 2026	DNB Carnegie Healthcare Conference, Stockholm
March 26 2026	DNB BackBay Nordic-American Healthcare Conference, New York City
April 28, 2026	Interim Report Q1 2026
July 21, 2026	Interim Report Q2 2026
October 20, 2026	Interim Report Q3 2026
February 2, 2027	Q4 Report 2026 & 2026 Annual Report

For further information

Contact details

Klaus Sindahl, Head of Investor Relations	+45 5363 0134	ksindahl@emblamedical.com
-------------------------------------------	---------------	---------------------------

Embla Medical corporate announcements by e-mail

If you wish to receive Embla Medical's e-mail alerts, please register on our website: <https://emblamedical.com/investor-relations>

Forward-looking statements

This press release includes "forward-looking statements" which involve risks and uncertainties that could cause actual results to differ materially from results expressed or implied by these statements. Össur hf. undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.

Embla Medical hf.

**Condensed Consolidated
Financial Statements**

31.12.2025

Embla Medical hf

Grjóthálsi 5

110 Reykjavík

Id-no. 560271-0189

Statement by the Board of Directors and President and CEO

The Condensed Consolidated Financial Statements of Embla Medical hf. for the period from 1 January 2025 to 31 December 2025 consist of the Financial Statements of Embla Medical hf. and its subsidiaries (together referred to as “the Company” or “Embla Medical”). The Condensed Consolidated Financial Statements are prepared in accordance with International Financial Reporting Standards for Interim Financial Reporting, IAS 34, as adopted by the EU. The Condensed Consolidated Financial Statements are neither audited nor reviewed by the Company's auditors.

The total Net sales of the Company amounted to USD 928.7 million and the Net profit amounted to USD 83.6 million. Total assets of the Company amounted to USD 1,730.5 million at the end of period, liabilities were USD 834.7 million and equity was USD 895.8 million.

It is our opinion that these Condensed Consolidated Financial Statements present all the information necessary to give a true and fair view of the Company's financial position at 31 December 2025 and financial performance and cash flow for the period ended 31 December 2025.

The Board of Directors and the President and CEO of Embla Medical hf. hereby confirm the Condensed Consolidated Financial Statements for the period from 1 January 2025 to 31 December 2025 with their signatures.

Reykjavík, 3 February 2026

Board of Directors

Niels Jacobsen
Chairman of the Board

Svafa Grönfeldt
Vice Chairman of the Board of Directors

Arne Boye Nielsen
Member of the Board of Directors

Alberto Esquenazi
Member of the Board of Directors

Tina Abild Olesen
Member of the Board of Directors

Caroline Vagner Rosenstand
Member of the Board of Directors

President and CEO

Sveinn Sölvason

Consolidated Income Statement

All amounts in USD '000	Notes	2025	2024	Q4 2025	Q4 2024
Net sales	3	928,689	854,889	256,691	224,781
Cost of goods sold		(350,134)	(320,189)	(98,625)	(82,663)
Gross profit		578,555	534,700	158,066	142,117
Other income / (expenses)		608	399	175	(86)
Sales and marketing expenses		(334,180)	(311,151)	(92,194)	(80,628)
Research and development expenses		(45,856)	(40,832)	(11,948)	(11,005)
General and administrative expenses		(73,824)	(69,964)	(21,662)	(18,532)
Earnings before interest and tax (EBIT)		125,303	113,153	32,438	31,867
Financial income		2,061	3,251	362	860
Financial expenses		(21,115)	(24,746)	(4,562)	(5,724)
Net exchange rate difference		(4,974)	(4,435)	1,253	(3,177)
Net financial expenses		(24,028)	(25,930)	(2,947)	(8,041)
Share in net profit of associates		6,661	3,340	1,127	1,055
Earnings before tax (EBT)		107,936	90,563	30,618	24,882
Income tax		(24,291)	(21,603)	(5,896)	(6,263)
Net profit		83,645	68,960	24,722	18,619
Attributable to:					
Owners of the Company		83,336	68,278	24,404	18,207
Non-controlling interests		309	682	318	413
Net profit		83,645	68,960	24,722	18,619
Earnings per share					
Basic earnings per share (US cent)		19.6	16.2	5.8	4.4
Diluted earnings per share (US cent)		19.6	16.2	5.8	4.4

Consolidated Statement of Comprehensive Income

All amounts in USD '000	2025	2024	Q4 2025	Q4 2024
Net profit	83,645	68,960	24,722	18,619
Items that may be reclassified subsequently to profit or loss:				
Change in cash flow hedges	(1,826)	1,832	(1,435)	1,676
Fair value changes of financial liabilities	0	88	0	88
Exchange difference on translating foreign operations	22,721	(11,175)	1,243	(5,773)
Income tax	4,997	(2,073)	627	(1,259)
Other comprehensive income, net of income tax	25,892	(11,328)	435	(5,268)
Total comprehensive income	109,537	57,632	25,158	13,352
Attributable to:				
Owners of the Company	109,228	56,950	24,839	12,939
Non-controlling interests	309	682	318	413
Total comprehensive income	109,537	57,632	25,158	13,352

Consolidated Balance Sheet

Assets

All amounts in USD '000	Notes	31.12.2025	31.12.2024
Property, plant and equipment	5	80,215	71,824
Right of use assets	6	162,514	127,802
Goodwill		835,560	776,306
Other intangible assets	7	106,908	96,645
Investment in associates		27,950	20,364
Other financial assets		3,966	2,704
Deferred tax assets		55,380	46,365
Non-current assets		1,272,493	1,142,010
Inventories		165,617	143,102
Accounts receivable		144,782	121,915
Other financial assets		0	1,475
Other assets		45,092	44,300
Cash and cash equivalents		102,507	86,163
Current assets		457,998	396,955
Total assets		1,730,491	1,538,965

Consolidated Balance Sheet

Equity and liabilities

All amounts in USD '000	31.12.2025	31.12.2024
Issued capital and share premium	98,470	93,464
Other reserves	(50,494)	(75,390)
Retained earnings	842,572	759,112
Shareholders equity	890,549	777,186
Non-controlling interest	5,254	3,513
Total equity	895,803	780,699
Borrowings	292,174	328,754
Lease liabilities	153,499	118,279
Deferred tax liabilities	39,788	37,478
Provisions	8,723	7,937
Deferred income	11,346	8,589
Other financial liabilities	19,588	47,946
Non-current liabilities	525,117	548,982
Borrowings	67,678	28,620
Lease liabilities	28,218	24,136
Accounts payable	32,825	27,275
Income tax payable	21,322	18,305
Provisions	16,315	12,615
Accrued salaries and related expenses	59,550	48,715
Other financial liabilities	35,673	10,258
Other liabilities	47,989	39,361
Current liabilities	309,571	209,284
Total liabilities	834,688	758,266
Total equity and liabilities	1,730,491	1,538,965

Consolidated Statement of Cash Flow

All amounts in USD '000	Notes	2025	2024	Q4 2025	Q4 2024
Earnings before interests and tax (EBIT)		125,303	113,153	32,438	31,867
Depreciation, impairment and amortization	5, 6, 7	60,619	55,973	15,501	14,636
Change in inventories		(8,594)	(5,928)	2,042	(641)
Change in receivables		(12,321)	(5,524)	7,578	688
Change in payables		11,326	(2,279)	7,237	4,505
Change in provisions		3,858	3,174	2,529	96
Other operating activities		(2,403)	1,828	(4,067)	2,770
Cash generated from operations		177,788	160,397	63,259	53,921
Interest received		1,984	3,238	313	870
Interest paid		(20,551)	(24,082)	(4,412)	(5,767)
Income tax paid		(26,603)	(23,487)	(8,772)	(7,070)
Net cash generated from operating activities		132,618	116,066	50,388	41,954
Purchase of fixed and intangible assets	5, 7	(32,332)	(39,227)	(8,055)	(8,003)
Acquisition of subsidiaries, net of cash in acquired entities		(4,087)	(65,020)	(812)	0
Payment of contingent consideration and deferred payments		(10,603)	(5,052)	(6,344)	(667)
Dividend received		4,083	2,585	99	2,174
Other investing activities		(3,186)	1,944	49	2,649
Cash flows used in investing activities		(46,126)	(104,770)	(15,064)	(3,847)
Proceeds from long-term borrowings		57,463	0	0	0
Repayments of long-term borrowings		(59,011)	0	(1,189)	0
Changes in revolving credit facility		(30,823)	39,787	(24,138)	(21,571)
Payments of lease liabilities		(27,500)	(24,379)	(7,131)	(6,438)
Increase in subsidiaries that does not affect control		(5,123)	(9,648)	0	(1,016)
Dividends from subsidiaries paid to non-controlling interests		(35)	0	0	0
Purchased treasury shares		(9,752)	0	(2,801)	0
Cash flows generated from financing activities		(74,782)	5,761	(35,259)	(29,025)
Net change in cash		11,710	17,056	65	9,082
Exchange rate effects on cash held in foreign currencies		4,634	(3,545)	368	(4,126)
Cash and cash equivalents at beginning of period		86,163	72,653	102,074	81,207
Cash and cash equivalents at end of period		102,507	86,163	102,507	86,163

Consolidated Statement of Changes in Equity

All amounts in USD '000	Share capital	Share premium	Other reserves	Retained earnings	Shareholders equity	Non-controlling interests	Total equity
Balance at 1 January 2024	4,781	61,479	(64,045)	699,667	701,883	3,123	705,005
Net profit				68,278	68,278	682	68,960
Change in cash flow hedges			1,466		1,466		1,466
Fair value changes of financial liabilities			66		66		66
Transl. diff. of shares in subsidiaries			(12,860)		(12,860)		(12,860)
Total comprehensive income	0	0	(11,328)	68,278	56,950	682	57,632
Put option for minority share in subsidiary			689		689		689
Share contract charge			602		602		602
Share contract vested/expired			(1,308)	1,308	0		0
Issued new shares	48	27,156			27,204		27,204
Change in non-controlling interests				(10,142)	(10,142)	(292)	(10,434)
Balance at 31 December 2024	4,829	88,635	(75,390)	759,112	777,186	3,513	780,699
Balance at 1 January 2025	4,829	88,635	(75,390)	759,112	777,186	3,513	780,699
Net profit				83,336	83,336	309	83,645
Change in cash flow hedges			(1,461)		(1,461)		(1,461)
Transl. diff. of shares in subsidiaries			27,353		27,353		27,353
Total comprehensive income	0	0	25,892	83,336	109,228	309	109,537
Payment of dividends					0	(35)	(35)
Share contract charge			1,970		1,970		1,970
Share contract vested/expired		185	(2,967)	2,706	(76)		(76)
Purchase of treasury shares	(16)	(9,736)			(9,752)		(9,752)
Issued new shares	23	14,550			14,573		14,573
Minority arising on acquisition					0	4,611	4,611
Change in non-controlling interests				(2,581)	(2,581)	(3,143)	(5,724)
Balance at 31 December 2025	4,836	93,634	(50,494)	842,572	890,549	5,254	895,803

Notes to the Condensed Consolidated Financial Statements

1. Summary of Material Accounting Policies

Statement of compliance

The Condensed Consolidated Financial Statements are prepared in accordance with International Financial Reporting Standard (IFRS) for Interim Financial Reporting, IAS 34 as adopted by the EU. The Condensed Consolidated Financial Statements are presented in accordance with the new and revised IFRS accounting standards and new interpretations (IFRIC), applicable for the period. New and amended IFRS accounting standards that are effective for the current year have minor impact on the Company's Financial Statements. The Company has not early applied new and revised IFRS accounting standards that have been issued but are not yet effective. The Financial Statements are presented in USD, which is the Company's functional currency. They do not include all of the information required for full Annual Consolidated Financial Statements and should be read in conjunction with the Company's Annual Consolidated Financial Statements for the period ended 31 December 2025. The Company's Annual Consolidated Financial Statements can be found on the Company's website www.emblamedical.com.

Basis of preparation

The Condensed Consolidated Financial Statements have been prepared under the historical cost basis except for certain financial instruments that are measured at fair value. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The Condensed Consolidated Financial Statements are presented in USD and all values are rounded to the nearest thousand ('000), except when otherwise indicated. This rounding may have impact on the total sum. The accounting policies adopted are consistent with those followed in the preparation of the Company's Annual Consolidated Financial Statements for the period ended 31 December 2025.

Notes to the Condensed Consolidated Financial Statements

2. Quarterly statements

	Full year 2025	Q4 2025	Q3 2025	Q2 2025	Q1 2025
Net sales	928,689	256,691	236,795	232,418	202,786
Cost of goods sold	(350,134)	(98,625)	(88,559)	(87,931)	(75,020)
Gross profit	578,555	158,066	148,236	144,487	127,766
Gross profit margin	62%	62%	63%	62%	63%
Other income / (expenses)	608	175	(382)	447	367
Sales and marketing expenses	(334,180)	(92,194)	(81,400)	(82,529)	(78,057)
Research and development expenses	(45,856)	(11,948)	(11,489)	(11,851)	(10,569)
General and administrative expenses	(73,824)	(21,662)	(18,065)	(16,817)	(17,280)
EBIT	125,303	32,438	36,900	33,737	22,227
Net financial expenses	(24,028)	(2,947)	(4,135)	(9,764)	(7,181)
Share in net profit of associates	6,661	1,127	1,220	3,701	613
EBT	107,936	30,618	33,984	27,674	15,659
Income tax	(24,291)	(5,896)	(8,203)	(6,561)	(3,631)
Net profit	83,645	24,722	25,782	21,113	12,027
EBITDA	185,922	47,939	52,850	48,666	36,467
EBITDA margin	20%	19%	22%	21%	18%

There were no special items in the above quarters.

3. Net Sales

	2025	2024	Q4 2025	Q4 2024
Sales by geographical segment:				
EMEA	457,445	394,869	130,689	100,750
Americas	398,516	392,898	107,320	106,768
APAC	72,728	67,122	18,681	17,263
Total	928,689	854,889	256,691	224,781
Sales by business segment:				
Prosthetics & Neuro Orthotics	513,408	451,306	140,940	118,834
Bracing & Supports	148,383	148,386	37,499	36,715
Internal product sales	(39,036)	(38,516)	(10,300)	(10,660)
External product sales	622,756	561,176	168,139	144,888
Patient Care	305,933	293,713	88,551	79,892
Total	928,689	854,889	256,691	224,781

Notes to the Condensed Consolidated Financial Statements

4. Sales and expenses split by main currencies

2025			Q4 2025		
	LCY	USD	%	LCY	USD
Sales					
USD	358,545	358,545	39%	97,796	97,796
EUR	251,970	285,142	31%	71,349	83,039
ISK	562,783	4,391	1%	168,832	1,349
SEK, NOK, DKK		107,189	12%		30,186
GBP, AUD, CAD & Other		173,422	19%		44,321
Total		928,689	100%		256,691
COGS and OPEX					
USD	306,591	306,591	38%	73,598	73,598
EUR	183,268	207,795	26%	58,307	67,860
ISK	11,522,513	89,679	11%	3,049,298	24,361
SEK, NOK, DKK		99,945	12%		26,588
GBP, MXN, CAD & Other		99,376	12%		31,846
Total		803,386	100%		224,252
2024			Q4 2024		
	LCY	USD	%	LCY	USD
Sales					
USD	350,524	350,524	41%	96,412	96,412
EUR	220,419	238,475	28%	56,958	60,792
ISK	508,430	3,684	0%	147,160	1,068
SEK, NOK, DKK		99,604	12%		26,202
GBP, AUD, CAD & Other		162,603	19%		40,307
Total		854,889	100%		224,781
COGS and OPEX					
USD	302,848	302,848	41%	78,446	78,446
EUR	164,563	178,000	24%	44,642	47,647
ISK	11,112,364	80,541	11%	2,826,323	20,509
SEK, NOK, DKK		91,609	12%		23,954
GBP, MXN, CAD & Other		88,738	12%		22,357
Total		741,736	100%		192,913

Currency split is derived by using best available information at each time.

Notes to the Condensed Consolidated Financial Statements

5. Property, plant and equipment

2025	Leasehold improvements	Machinery & equipment	Office equipment	Computer equipment	Total
Cost					
At 1 January	51,273	80,116	14,939	13,941	160,269
Additions	6,921	10,675	1,197	3,279	22,073
Business Combinations	2,294	599	403	63	3,359
Eliminated on disposal	(46)	(178)	(21)	(130)	(375)
Fully depreciated assets	(94)	(522)	(189)	(2,224)	(3,029)
Exchange rate differences	2,399	1,539	1,534	833	6,304
At 31 December 2025	62,745	92,228	17,862	15,764	188,600
Depreciation					
At 1 January	19,654	50,499	9,850	8,442	88,445
Charge for the period	5,897	8,128	1,684	3,658	19,367
Eliminated on disposal	(23)	(183)	(19)	(106)	(331)
Fully depreciated assets	(94)	(522)	(189)	(2,224)	(3,029)
Exchange rate differences	1,652	888	849	545	3,935
At 31 December 2025	27,086	58,810	12,175	10,315	108,385
At 31 December 2025	35,660	33,418	5,688	5,449	80,215
Depreciation classified by functional category:					
	2025	2024	Q4 2025	Q4 2024	
Cost of goods sold	9,739	9,850	2,356	2,568	
Sales and marketing expenses	4,532	3,922	1,322	893	
Research and development expenses	1,303	773	303	196	
General and administrative expenses	3,793	4,030	1,075	1,071	
Total	19,367	18,575	5,056	4,726	

Notes to the Condensed Consolidated Financial Statements

6. Leases

Right of use assets

2025	Buildings & sites	Machinery & equipment	Total
At 1 January	123,789	4,012	127,802
Additions and renewals	53,766	2,817	56,583
Depreciation charge and impairment for the period	(26,573)	(2,696)	(29,269)
Eliminated on disposal and termination	(2,790)	0	(2,790)
Exchange rate differences	9,664	524	10,188
At 31 December 2025	157,857	4,658	162,514

Depreciation and impairment classified by functional category:	2025	2024	Q4 2025	Q4 2024
Cost of goods sold	11,731	10,093	2,775	2,645
Sales and marketing expenses	9,161	5,047	2,277	1,323
Research and development expenses	3,149	3,028	783	794
General and administrative expenses	5,227	7,065	1,281	1,852
Total	29,269	25,233	7,116	6,613

Notes to the Condensed Consolidated Financial Statements

7. Other intangible assets

2025	Customer & distribution relationships	Patents & development costs	Trademarks	Software & other	Total
Cost					
At 1 January	36,701	32,214	8,156	63,176	140,246
Additions	0	960	39	1,409	2,408
Additions - internally generated	0	0	0	7,852	7,852
Business Combinations	7,823	478	0	79	8,380
Fully amortized assets	0	0	(279)	(3,197)	(3,476)
Exchange rate differences	3,035	511	712	131	4,389
At 31 December 2025	47,559	34,163	8,627	69,448	159,798
Amortization					
At 1 January	9,393	9,789	523	23,896	43,601
Charge for the period	3,668	2,311	104	5,901	11,984
Fully amortized assets	0	0	(279)	(3,197)	(3,476)
Exchange rate differences	478	279	0	23	781
At 31 December 2025	13,540	12,379	348	26,623	52,889
At 31 December 2025	34,019	21,784	8,280	42,825	106,908
Amortization classified by functional category:					
	2025	2024	Q4 2025	Q4 2024	
Cost of goods sold	883	1,577	194	337	
Sales and marketing expenses	6,819	6,377	1,761	2,059	
Research and development expenses	1,882	1,691	542	432	
General and administrative expenses	2,400	2,520	832	469	
Total	11,984	12,165	3,329	3,297	